These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37021547)

  • 1. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
    O'Brien C; Ling T; Berman JM; Culp-Hill R; Reisz JA; Rondeau V; Jahangiri S; St-Germain J; Macwan V; Astori A; Zeng A; Hong JY; Li M; Yang M; Jana S; Gamboni F; Tsao E; Liu W; Dick JE; Lin H; Melnick A; Tikhonova A; Arruda A; Minden MD; Raught B; D'Alessandro A; Jones CL
    Haematologica; 2023 Sep; 108(9):2343-2357. PubMed ID: 37021547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance via Controlling HES1-Dependent Fatty Acid Oxidation.
    Zhang Y; Shen Y; Wei W; Wang W; Jiang D; Ren Y; Peng Z; Fan Q; Cheng J; Ma J
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold.
    Griessinger E; Pereira-Martins D; Nebout M; Bosc C; Saland E; Boet E; Sahal A; Chiche J; Debayle D; Fleuriot L; Pruis M; De Mas V; Vergez F; Récher C; Huls G; Sarry JE; Schuringa JJ; Peyron JF
    Cancer Res; 2023 Aug; 83(15):2461-2470. PubMed ID: 37272750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
    Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
    Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirt3 modulates fatty acid oxidation and attenuates cisplatin-induced AKI in mice.
    Li M; Li CM; Ye ZC; Huang J; Li Y; Lai W; Peng H; Lou TQ
    J Cell Mol Med; 2020 May; 24(9):5109-5121. PubMed ID: 32281286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
    Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
    J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
    Jones CL; Stevens BM; D'Alessandro A; Reisz JA; Culp-Hill R; Nemkov T; Pei S; Khan N; Adane B; Ye H; Krug A; Reinhold D; Smith C; DeGregori J; Pollyea DA; Jordan CT
    Cancer Cell; 2018 Nov; 34(5):724-740.e4. PubMed ID: 30423294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
    Lim INX; Nagree MS; Xie SZ
    Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirtuin 3 improves fatty acid metabolism in response to high nonesterified fatty acids in calf hepatocytes by modulating gene expression.
    Liu L; Xing D; Du X; Peng T; McFadden JW; Wen L; Lei H; Dong W; Liu G; Wang Z; Su J; He J; Li X
    J Dairy Sci; 2020 Jul; 103(7):6557-6568. PubMed ID: 32331890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD
    Yang X; Ge G; Wang H; Liu T; Pan D; Zhao X; Chen X; Wang J; Zhang J; Zhang K; Yao D
    Eur J Med Chem; 2024 Oct; 276():116689. PubMed ID: 39053191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2.
    Culp-Hill R; Stevens BM; Jones CL; Pei S; Dzieciatkowska M; Minhajuddin M; Jordan CT; D'Alessandro A
    Metabolites; 2023 Mar; 13(4):. PubMed ID: 37110126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity.
    Li S; Dou X; Ning H; Song Q; Wei W; Zhang X; Shen C; Li J; Sun C; Song Z
    Hepatology; 2017 Sep; 66(3):936-952. PubMed ID: 28437863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy.
    Pei S; Shelton IT; Gillen AE; Stevens BM; Gasparetto M; Wang Y; Liu L; Liu J; Brunetti TM; Engel K; Staggs S; Showers W; Sheth AI; Amaya ML; Minhajuddin M; Winters A; Patel SB; Tolison H; Krug AE; Young TN; Schowinsky J; McMahon CM; Smith CA; Pollyea DA; Jordan CT
    Cancer Discov; 2023 Sep; 13(9):2032-2049. PubMed ID: 37358260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turning Down the Temperature on Leukemia Stem Cells.
    Jones CL
    Cancer Res; 2023 Aug; 83(15):2441-2442. PubMed ID: 37525977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.
    He L; Arnold C; Thoma J; Rohde C; Kholmatov M; Garg S; Hsiao CC; Viol L; Zhang K; Sun R; Schmidt C; Janssen M; MacRae T; Huber K; Thiede C; Hébert J; Sauvageau G; Spratte J; Fluhr H; Aust G; Müller-Tidow C; Niehrs C; Pereira G; Hamann J; Tanaka M; Zaugg JB; Pabst C
    EMBO Mol Med; 2022 Apr; 14(4):e14990. PubMed ID: 35253392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.
    Hirschey MD; Shimazu T; Goetzman E; Jing E; Schwer B; Lombard DB; Grueter CA; Harris C; Biddinger S; Ilkayeva OR; Stevens RD; Li Y; Saha AK; Ruderman NB; Bain JR; Newgard CB; Farese RV; Alt FW; Kahn CR; Verdin E
    Nature; 2010 Mar; 464(7285):121-5. PubMed ID: 20203611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.